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Abstract:  Background: We have previously shown that mouse whole bone marrow cell (BMC) extract results in 
improvement of cardiac function and decreases scar size in a mouse model of myocardial infarction (MI), in the absence 
of intact cells. It is not clear if these results are translatable to extracts from human BMC (hBMC) or mononuclear cells 
(hMNC), which would have significant clinical implications. 
Methods: Male C57BL/6J (10-12 weeks old) mice were included in this study. MI was created by permanent ligation of 
the left anterior descending artery. Animals were randomized into three groups to receive ultrasound-guided myocardial 
injections with either hBMCs extract (n=6), hMNCs extract (n=8) or control with 0.5% bovine serum albumin (BSA) 
(n=7). Cardiac function was assessed by echocardiography at baseline, 2 and 28 days post-MI. Infarct size and vascularity 
was assessed at 28 days post-MI.  
Results: hBMC and hMNC extract preserve cardiac function and result in smaller scar size post-MI when compared with 
the control group.  
Conclusions: The current study for the first time reports that hBMC and hMNC extracts improve cardiac function post-MI 
in a mouse MI model. Further studies are necessary to fully address the potential clinical benefits of these therapies.  
Keywords: Bone marrow cells, stem cell therapy, paracrine effect, myocardial infarct. 
INTRODUCTION 
  Cell therapy has emerged as a potential treatment option 
for cardiac ischemic disease. The benefits of this new 
approach have been tested in several clinical trials using 
bone-marrow-derived cells (BMCs) post myocardial 
infarction (MI) [1-6]. Growing evidence suggests that 
paracrine mechanisms, rather than cell differentiation or 
fusion, are responsible for the beneficial effects of cell 
therapy in improving cardiac function post-MI [7-12]. We 
have recently shown that intact mouse BMCs are not 
necessary to obtain benefits and that the intracellular 
components within mouse whole BMCs can reduce MI size 
and improve cardiac function when administered early 
following MI [12]. However, the impact of human BMC 
(hBMC) extract and human mononuclear cells (hMNC) 
extract on cardiac functional changes post-MI has not been 
investigated. Therefore, in this study, we take the first step 
towards clinical applicability by evaluating the efficacy of 
extracts obtained from hBMC and hMNC in a mouse model 
of MI.  
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MATERIAL AND METHODS 
  Male C57BL/6J (10-12 weeks old) mice were used for all 
experiments and were handled according to the guidelines of 
the Institutional Animal Care and Use Committee of the 
University of California, San Francisco.  
MYOCARDIAL INFARCTION MODEL CREATION 
AND CARDIAC FUNCTION EVALUATION 
  MI was surgically-induced by permanent ligation of the 
mid left anterior descending coronary artery as previously 
described [12, 13]. Cardiac function was evaluated by 
echocardiography at baseline, 2 days post-MI (before 
injection), and at day 28 post-MI as previously described   
by our group [12-15]. Briefly, echocardiography was 
accomplished  under isoflurane anesthesia (isoflurane 
1.5%/O2 1.0 L/min) with the use of a Vevo 660 
(VisualSonics, Toronto, Canada) equipped with a 30 MHz 
transducer. Two-dimensional echocardiography was used to 
determine left ventricle ejection fraction (LVEF) from end-
diastolic and end-systolic volumes (EDV and ESV). Three 
cycles were measured for each assessment and the average 
values were obtained. 
CELL AND EXTRACT PREPARATION 
  Fresh human whole BMCs were harvested from four 
young healthy males (mean age 26 ± 2 years). The MNCs Human Bone Marrow Extract after Myocardial Infarction  The Open Cardiovascular Medicine Journal, 2012, Volume 6    39 
fraction was selected using Ficoll gradient as previously 
described [16]. The concentration of the cells was adjusted to 
10
5 viable cells/l in phosphate-buffered saline containing 
0.1% Tween 20, pH 7.4-20 OptiMax wash basic phosphate 
buffer saline (BPBS) with 0.5% bovine serum albumin 
(BSA). Cell-free extract was prepared by subjecting the   
cells to three freeze-thaw cycles using an ethanol/dry ice 
bath to lyse cells, followed by centrifugation at 14,000 rpm 
in a microcentrifuge to remove insoluble material. This 
resulted in an extract containing the intracellular soluble 
material. 
ULTRASOUND-GUIDED INJECTIONS 
  After echocardiography on day 2 post-MI, animals were 
randomized into three groups to receive ultrasound-guided 
myocardial injections with either human BMCs extract 
(hBMC) (n=6), human MNCs extract (hMNC) (n=8) or 
control with 0.5% BSA ( n=7) as previously described [13]. 
Each heart was injected at day 3 post-MI with the extract 
from 110
6 cells in 10 l, or 10 l BPBS/BSA, divided into 
two 5 l injections into the anterior peri-infarct wall of the 
left ventricle.  
TISSUE ANALYSIS 
  At day 28, the hearts were injected with a saturated 
solution of KCl (0.1 ml) to arrest in diastole. Heart samples 
were collected for histological staining. Scar size in the left 
ventricle and blood vessel density was analyzed for each 
group at day 28 post-MI as previously described [12]. 
Briefly, sections from the mid-ventricular level were 
examined for detection of infarct size, and blood vessel 
density using Masson’s trichrome-staining, and alpha-
smooth muscle actin (SMA; Sigma-Aldrich, St. Louis, MO; 
1:100 dilution), respectively. Blood vessel density was 
analyzed separately from the infarct zone, the border zone 
and the remote zone. Border zone was defined as an area 
containing one third of infarcted myocardium. 
STATISTICAL ANALYSIS 
  Data were presented as mean ± SD. For the comparison 
of
 echocardiographic functional parameters and histological 
data (infarct size and blood vessel density) between groups,
 
an ANOVA with Fisher’s post hoc test was used. For the 
comparison of LVEF changes at day 2 and day 28 within 
each group, paired t test was used. A p-value of <0.05 two-
sided was considered significant. 
RESULTS  
Cardiac Function Over Time  
  After the induction of MI, all animals had an expected 
decrease in the left ventricular ejection fraction (LVEF) from 
56.4 ± 2.6% to 36.7 ± 3.2% (p<0.001). After therapy, only 
the hBMC and hMNC cell extract groups resulted in 
improvement of the LVEF at day 28 post-MI (Figs. 1 and 2). 
The control group resulted in no cardiac functional benefit 
but rather continued worsening of LVEF over time, 
consistent with our prior report.
12 hMNC extract resulted in 
significantly less ventricular remodeling post-MI as assessed 
by cardiac volumetric analysis and there was a trend for 
smaller ventricular volumes with the hBMCs compared to 
control (Fig. 3). 
INFARCT SCAR 
  At day 28, both hBMC and hMNC extracts were 
associated with a significantly smaller infarct scar compared 
to the control group as shown in Fig. (4).  
BLOOD VESSEL DENSITY EVALUATION  
  HMNC extract and hBMC extract had more vessels in 
the border zone than the control group but only the hBMC 
 
Fig. (1). Echocardiographic changes in the left ventricular ejection fraction (LVEF) from day 2 to day 28 post-MI. Both human  
BMC and MNC extracts significantly improved % LVEF change compared with control which showed continued deterioration of the LVEF 
post-MI. 40    The Open Cardiovascular Medicine Journal, 2012, Volume 6  Angeli et al. 
 
Fig. (2). This figure demonstrates representative echocardiograms of the various groups: The left image shows an example of a 
remodeled heart from the control group with LV dilation and apical aneurysm (red arrow). Right upper panel is an example of a heart treated 
with hBMC-extract and the right lower panel shows an example of an animal treated with hMNCs-extract. Both of these demonstrate 
limitation of LV dilation and less geometric changes compared to the control group. 
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Fig. (3). contd…. 
B   
Fig. (3). Changes in left ventricular volumes over time following myocardial infarction by echocardiography. (A) End systolic volume 
and (B) end diastolic volume at day 2 and at 4 weeks post myocardial infarction. Data are shown as mean ± SD. At day 2, pre-MI, all three 
groups have similar ESV and EDV values. hMNC extract was associated with significantly smaller volumes at day 28 compared to the 
control group and there was a trend towards smaller volumes with the hBMC extract but this did not reach statistical significance. 
 
Fig. (4). Human BMC and MNC extracts result in smaller infarct scar sizes compared to controls. 
 
group reached statistical significance (Fig. 5). There was no 
difference in blood vessel counts in the infarct or remote 
zones (data not shown).  
DISCUSSION 
  In this study, we have demonstrated that extracts derived 
from human BMC and MNC preserve cardiac function and 
decrease scar size post-MI when compared to the control 
group. Mouse and human bone marrow cells have several 
differences, which would potentially result in different 
outcomes as therapeutic agents [17-20]. Therefore, our 
results expand our previous report with the mouse BMC 
extract to human cells reinforcing that intact cells do not 
appear to be necessary to obtain cardiac benefit post-MI.  
  We and others have reported that mouse BMCs can aid in 
tissue preservation post-MI via a paracrine mechanism [12]. 
In our previous report, we demonstrated an early increase in 
vascularity at day 6 but at day 28 after injection of extracts 
derived from mouse BMC, this increase in vascularity had 
equilibrated back to the expected level in normal tissue, 
while the overall cardiac functional benefits appear to have 
lasted for a longer time period. We hypothesized that 
increased vascularity early after MI rescued ischemic 
cardiomyocytes from apoptosis, thereby salvaging 42    The Open Cardiovascular Medicine Journal, 2012, Volume 6  Angeli et al. 
myocardium. These results are consistent with prior studies 
by Schuleri et al., [21] who demonstrated that an early 
increase in myocardial perfusion resulted in longer term 
functional improvement. Indeed, these authors also show no 
increase in vessel number after 8 weeks.  
  In the current study, although only hBMC extract was 
noted to have more vessels in the border zone at day 28, both 
treatment groups resulted in improvement of cardiac 
function and led to a reduction in infarct size (Figs. 1-3). 
Potential reasons for this difference should be highlighted. 
First, this could be due to a small sample size which may 
have affected statistical power. Second, several paracrine 
factors and cytokines might be differentially expressed 
within the whole BMCs vs MNCs extract. The detailed 
mechanism(s) and which paracrine factor(s) within each 
extract lead(s) to cardiac functional improvement following 
therapy are not yet fully understood, and this continues to be 
an important area of investigation within the field. Lastly, we 
only assessed the vessel count at day 28 post MI and not at 
an earlier timepoint. As discussed previously, we and others 
have shown that increased vascularity early after MI rescues 
ischemic cardiomyocytes from apoptosis, thereby salvaging 
myocardium, and that increased vascularity was not 
necessarily found at a later timepoint (12, 21). 
  The mechanisms underlying the beneficial effects of 
BMC implantation into post-MI hearts are complex and 
controversial. Identification of cellular factors present in the 
lysates with anti-apoptotic and cardio-protective properties 
are of key interest in the search for effective clinical 
therapies and gain insight into the possible mechanisms of 
cardiac functional improvement.  
  Additionally, there is controversy in the cardiology field 
as to whether human BMCs or MNCs are more optimal cells 
for human clinical trials, and here we report that the extract 
from either was beneficial and that neither intact cell is 
necessary to result in cardiac functional benefit post-MI. The 
use of the cell extract rather than cells themselves is an 
important strategy in the development of novel therapies 
post-MI. Use of the extract eliminates the issues of cell 
rejection for allogeneic cells and negates the need for 
invasive bone marrow harvesting for autologous cell 
transplantation. The extract as a whole, or factors within the 
extract, can be given at the time of an acute coronary 
syndrome as an “off the shelf” medication at the time of 
coronary reperfusion. Which factor(s) within the human 
extract results in cardiac functional improvement is a topic 
of intense investigation at the present time.  
  Our study has several limitations. First, we did not assess 
vessel counts at an early timepoint post-MI. In addition, 
having human cell control groups would potentially allow us 
to confirm the non-superiority of live cells compared with 
the cell extracts. However, the use of human cells in a mouse 
model would require changing the animal model including: 
use of immunocompromised animals (to avoid cell rejection) 
and antibiotic therapy. Use of cell lysate (even from human 
derived source) negates the need for the use of 
immunocompromised animals or antibiotic therapy. For 
these reasons, the whole cell group was not included in the 
current study to avoid these confounding factors which 
would then make our model not as clinically translatable and 
impact our ability to correlate the current data with our 
previous findings using mouse BMC. 
  In conclusion, our results show for the first time that 
hBMC and hMNC extracts improve cardiac function post-
MI in a mouse model. Further studies should evaluate the 
benefits of the cellular extract and identify the cellular 
factors present within the extract with cardio-protective 
properties.  
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Fig. (5). HMNC extract and hBMC extract had more vessels in the border zone than the control group but only the hBMC group reached 
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BMC  =  Bone marrow cell 
MI =  Myocardial  infarct 
hBMC =  Human  BMC 
hMNC  =  Human mononuclear cells 
LVEF  =  Left ventricle ejection fraction 
EDV =  End-diastolic  volume 
ESV =  End-systolic  volumes 
BPBS =  Basic  phosphate buffered saline 
SMA =  Alpha-smooth  muscle  actin 
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